Limitations of Conventional Therapy and Transitioning to PTH Replacement in Hypoparathyroidism

Dr. Ferenczi reviews the 2025 European Society of Endocrinology monitoring cadence: after any dose change, biochemical monitoring should occur within one to two weeks. Routine stable monitoring should include albumin-adjusted or ionized calcium, phosphate, magnesium, creatinine, and eGFR every three to six months, with 24-hour urine calcium every one to two years—an early warning marker for renal trajectory. PTH levels should be checked approximately annually to assess for recovery of endogenous function, particularly in postsurgical cases where late recovery can occur beyond 12 months. She notes her disagreement with the guideline recommendation discouraging routine renal ultrasound, preferring to use it as a scheduled surveillance tool. The core adjustment principle on conventional therapy is to target the lowest serum calcium compatible with symptom freedom—not to chase normal calcemia.

Regarding transition triggers, Dr. Ferenczi frames inadequate control as a disjunctive list: any single criterion can justify the switch to PTH replacement. These include symptomatic hypocalcemia, hyperphosphatemia, renal insufficiency, hypercalciuria, poor quality of life, calcium fluctuations requiring hospitalization, GI intolerance of large calcium doses, malabsorption, or high conventional dose requirements—specifically calcium exceeding 2 g/day or active vitamin D exceeding 2 mcg/day. She describes the high-dose threshold as a concrete signal that conventional therapy is physiologically failing.

Comorbidities pulling toward earlier PTH replacement include renal disease in any form (CKD, nephrolithiasis, nephrocalcinosis, or hypercalciuria), GI malabsorption and bariatric surgery, osteoporosis requiring antiresorptive therapy, cardiovascular disease with hypertension, and a high overall comorbidity burden that raises the stakes of calcium swings and increases cardiovascular risk.

In the next episode, "Palopegteriparatide in Hypoparathyroidism: Mechanism, Long-Term Efficacy, and Clinical Experience," Dr. Lubitz explains how palopegteriparatide works as a prodrug, and Dr. Shoback reviews four-year clinical trial outcomes, patient-reported quality-of-life improvements, and real-world clinical experience with this PTH replacement therapy.